Johnson & Johnson annual diluted eps
Diluted EPSBasic EPS
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Johnson & Johnson EPS History: Annual & Quarterly (JNJ)
Johnson & Johnson's diluted EPS was $11.03 for fiscal 2025.
View full Johnson & Johnson company overviewJohnson & Johnson annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2025 | 2025-12-28 | $11.03 | $11.13 | $5.24 | +90.50% |
| 2024 | 2024-12-29 | $5.79 | $5.84 | -$7.93 | −57.80% |
| 2023 | 2023-12-31 | $13.72 | $13.88 | $6.99 | +103.86% |
| 2022 | 2023-01-01 | $6.73 | $6.83 | -$1.08 | −13.83% |
| 2021 | 2022-01-02 | $7.81 | $7.93 | $2.30 | +41.74% |
| 2020 | 2021-01-04 | $5.51 | $5.59 | -$0.12 | −2.13% |
| 2019 | 2019-12-29 | $5.63 | $5.72 | $0.02 | +0.36% |
| 2018 | 2018-12-30 | $5.61 | $5.70 | $5.14 | +1093.62% |
| 2017 | 2017-12-31 | $0.47 | $0.48 | -$5.46 | −92.07% |
| 2016 | 2017-01-01 | $5.93 | $6.04 | $0.45 | +8.21% |
| 2015 | 2016-01-03 | $5.48 | $5.56 | -$0.22 | −3.86% |
| 2014 | 2014-12-28 | $5.70 | $5.80 | $0.89 | +18.50% |
| 2013 | 2013-12-29 | $4.81 | $4.92 | $0.95 | +24.61% |
| 2012 | 2012-12-30 | $3.86 | $3.94 | $0.37 | +10.60% |
| 2011 | 2012-01-01 | $3.49 | $3.54 | -$1.29 | −26.99% |
| 2010 | 2011-01-02 | $4.78 | $4.85 | $0.38 | +8.64% |
| 2009 | 2010-01-03 | $4.40 | $4.45 | -$0.17 | −3.72% |
| 2008 | 2008-12-28 | $4.57 | $4.62 | $0.94 | +25.90% |
| 2007 | 2007-12-30 | $3.63 | $3.67 | — | — |
Johnson & Johnson quarterly diluted eps
Diluted EPSBasic EPS
Q2.08
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Diluted EPS | Basic EPS | Change | YoY change |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-28 | $2.27 | $2.30 | -$0.02 | −0.87% |
| Q1 2026 | 2026-03-29 | $2.14 | $2.17 | -$2.40 | −52.86% |
| Q4 2025 | 2025-12-28 | $2.10 | $2.12 | — | — |
| Q3 2025 | 2025-09-28 | $2.12 | $2.14 | $1.01 | +90.99% |
| Q2 2025 | 2025-06-29 | $2.29 | $2.30 | $0.36 | +18.65% |
| Q1 2025 | 2025-03-30 | $4.54 | $4.57 | $3.20 | +238.81% |
| Q3 2024 | 2024-09-29 | $1.11 | $1.12 | -$9.10 | −89.13% |
| Q2 2024 | 2024-06-30 | $1.93 | $1.95 | -$0.03 | −1.53% |
| Q1 2024 | 2024-03-31 | $1.34 | $1.35 | $1.37 | — |
| Q4 2023 | 2023-12-31 | $1.67 | $1.68 | $0.34 | +25.56% |
| Q3 2023 | 2023-10-01 | $10.21 | $10.32 | $8.53 | +507.74% |
| Q2 2023 | 2023-07-02 | $1.96 | $1.98 | $0.16 | +8.89% |
| Q1 2023 | 2023-04-02 | -$0.03 | -$0.03 | -$1.96 | — |
| Q4 2022 | 2023-01-01 | $1.33 | $1.35 | — | — |
| Q3 2022 | 2022-10-02 | $1.68 | $1.70 | $0.31 | +22.63% |
| Q2 2022 | 2022-07-03 | $1.80 | $1.83 | -$0.55 | −23.40% |
| Q1 2022 | 2022-04-03 | $1.93 | $1.96 | -$0.39 | −16.81% |
| Q3 2021 | 2021-10-03 | $1.37 | $1.39 | $0.04 | +3.01% |
| Q2 2021 | 2021-07-04 | $2.35 | $2.38 | $0.99 | +72.79% |
| Q1 2021 | 2021-04-04 | $2.32 | $2.35 | $0.15 | +6.91% |
| Q3 2020 | 2020-09-27 | $1.33 | $1.35 | $0.67 | +101.52% |
| Q2 2020 | 2020-06-28 | $1.36 | $1.38 | -$0.72 | −34.62% |
| Q1 2020 | 2020-03-29 | $2.17 | $2.20 | $0.78 | +56.12% |
| Q4 2019 | 2019-12-29 | $1.50 | $1.52 | $0.38 | +33.93% |
| Q3 2019 | 2019-09-29 | $0.66 | $0.67 | -$0.78 | −54.17% |
| Q2 2019 | 2019-06-30 | $2.08 | $2.11 | $0.63 | +43.45% |
| Q1 2019 | 2019-03-31 | $1.39 | $1.41 | -$0.21 | −13.13% |
| Q4 2018 | 2018-12-30 | $1.12 | $1.14 | $5.11 | — |
| Q3 2018 | 2018-09-30 | $1.44 | $1.47 | $0.07 | +5.11% |
| Q2 2018 | 2018-07-01 | $1.45 | $1.47 | $0.05 | +3.57% |
| Q1 2018 | 2018-04-01 | $1.60 | $1.63 | -$0.01 | −0.62% |
| Q4 2017 | 2017-12-31 | -$3.99 | -$3.99 | -$5.37 | — |
| Q3 2017 | 2017-10-01 | $1.37 | $1.40 | -$0.16 | −10.46% |
| Q2 2017 | 2017-07-02 | $1.40 | $1.42 | -$0.03 | −2.10% |
| Q1 2017 | 2017-04-02 | $1.61 | $1.63 | $0.02 | +1.26% |
| Q4 2016 | 2017-01-01 | $1.38 | $1.41 | $0.23 | +20.00% |
| Q3 2016 | 2016-10-02 | $1.53 | $1.56 | $0.33 | +27.50% |
| Q2 2016 | 2016-07-03 | $1.43 | $1.46 | -$0.18 | −11.18% |
| Q1 2016 | 2016-04-03 | $1.59 | $1.62 | $0.06 | +3.92% |
| Q4 2015 | 2016-01-03 | $1.15 | $1.16 | $0.26 | +29.21% |
| Q3 2015 | 2015-09-27 | $1.20 | $1.21 | -$0.46 | −27.71% |
| Q2 2015 | 2015-06-28 | $1.61 | $1.63 | $0.10 | +6.62% |
| Q1 2015 | 2015-03-29 | $1.53 | $1.55 | -$0.11 | −6.71% |
| Q4 2014 | 2014-12-28 | $0.89 | $0.90 | -$0.34 | −27.64% |
| Q3 2014 | 2014-09-28 | $1.66 | $1.69 | $0.62 | +59.62% |
| Q2 2014 | 2014-06-29 | $1.51 | $1.53 | $0.18 | +13.53% |
| Q1 2014 | 2014-03-30 | $1.64 | $1.67 | $0.42 | +34.43% |
| Q4 2013 | 2013-12-29 | $1.23 | $1.25 | $0.32 | +35.16% |
| Q3 2013 | 2013-09-29 | $1.04 | $1.06 | -$0.01 | −0.95% |
| Q2 2013 | 2013-06-30 | $1.33 | $1.36 | $0.83 | +166.00% |
| Q1 2013 | 2013-03-31 | $1.22 | $1.25 | -$0.19 | −13.48% |
| Q4 2012 | 2012-12-30 | $0.91 | $0.93 | $0.83 | +1037.50% |
| Q3 2012 | 2012-09-30 | $1.05 | $1.08 | -$0.10 | −8.70% |
| Q2 2012 | 2012-07-01 | $0.50 | $0.51 | -$0.50 | −50.00% |
| Q1 2012 | 2012-04-01 | $1.41 | $1.43 | $0.16 | +12.80% |
| Q4 2011 | 2012-01-01 | $0.08 | $0.08 | -$0.62 | −88.57% |
| Q3 2011 | 2011-10-02 | $1.15 | $1.17 | -$0.08 | −6.50% |
| Q2 2011 | 2011-07-03 | $1.00 | $1.01 | -$0.23 | −18.70% |
| Q1 2011 | 2011-04-03 | $1.25 | $1.27 | -$0.37 | −22.84% |
| Q4 2010 | 2011-01-02 | $0.70 | $0.71 | -$0.09 | −11.39% |
| Q3 2010 | 2010-10-03 | $1.23 | $1.24 | $0.03 | +2.50% |
| Q2 2010 | 2010-07-04 | $1.23 | $1.25 | $0.08 | +6.96% |
| Q1 2010 | 2010-04-04 | $1.62 | $1.64 | $0.36 | +28.57% |
| Q4 2009 | 2010-01-03 | $0.79 | $0.80 | — | — |
| Q3 2009 | 2009-09-27 | $1.20 | $1.21 | $0.03 | +2.56% |
| Q2 2009 | 2009-06-28 | $1.15 | $1.16 | -$0.02 | −1.71% |
| Q1 2009 | 2009-03-29 | $1.26 | $1.27 | — | — |
| Q3 2008 | 2008-09-28 | $1.17 | $1.19 | — | — |
| Q2 2008 | 2008-06-29 | $1.17 | $1.18 | — | — |
Johnson & Johnson diluted eps trends
Over the last five fiscal years, Johnson & Johnson's diluted eps increased from $5.51 to $11.03, a change of $5.52. The latest reported quarter, Q2 2026, shows $2.27.
About the metric
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
Calculation and source
SEC-reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from SEC filings. Historical EPS values are adjusted to the current share basis when SEC-reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Johnson & Johnson source filings ↗Community posts
J&J reports surgery-comparator benefit for Erleada in prostate cancer
Johnson & Johnson ($JNJ) reported new PROTEUS substudy results comparing Erleada plus hormone therapy before and after prostate surgery with surgery alone. Among 408 patients with high-risk localized or locally advanced disease, the regimen ...
J&J reports early prostate-cancer responses for experimental oral drug
Johnson & Johnson ($JNJ) disclosed early results for oral JNJ-6143 in heavily pretreated advanced prostate cancer. Among 31 evaluable patients receiving 50 milligrams, 77% achieved at least a 50% PSA decline. Confirmed tumor responses occur ...
Carvykti follow-up finds half of a small cohort progression-free at five years
Johnson & Johnson ($JNJ) and Legend Biotech ($LEGN) reported five-year follow-up from 20 patients in the Phase 2 CARTITUDE-2 Cohort A study of Carvykti. Ten remained alive without disease progression or further anti-myeloma treatment after ...
Johnson & Johnson says Tremfya meets axial psoriatic-arthritis trial goals
Johnson & Johnson ($JNJ) said Tremfya met the primary and key secondary endpoints in STAR, a randomized, double-blind Phase 4 study in patients with axial manifestations of psoriatic arthritis. The company reported improvement over placebo ...
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...
